Back to top
more

BioNTech (BNTX)

(Delayed Data from NSDQ)

$111.77 USD

111.77
1,320,094

-2.70 (-2.36%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $111.72 -0.05 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Moderna (MRNA) Up 20% on Upbeat Data From Cancer Jab Study

by Zacks Equity Research

Data from a mid-stage study showed that Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda reduces the risk of recurrence/death by 44% in melanoma patients.

All You Need to Know About BioNTech SE Sponsored ADR (BNTX) Rating Upgrade to Buy

by Zacks Equity Research

BioNTech SE Sponsored ADR (BNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Can BioNTech SE Sponsored ADR (BNTX) Climb 31% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for BioNTech SE Sponsored ADR (BNTX) points to a 30.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Is BioNTech (BNTX) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Pfizer (PFE), BNTX's COVID-Flu Combo Jab Gets FDA Fast Track Tag

by Zacks Equity Research

The FDA grants fast-track designation to Pfizer (PFE)/BioNTech's (BNTX) early-stage combination vaccine candidate, which targets two respiratory diseases - influenza and COVID-19.

FDA Approves Pfizer, Moderna's Omicron COVID Jabs in Younger Kids

by Zacks Equity Research

Amid a rise in seasonal respiratory illnesses in younger children across the country, the FDA broadens the label of authorized bivalent Omicron BA.4/BA.5-adapted vaccines to include children as young as six months.

Pfizer (PFE) Seeks FDA Nod for Bivalent COVID Jab in Infants

by Zacks Equity Research

Pfizer (PFE) and partner BioNTech seek label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in young children under five years.

BioNTech (BNTX) Inks Research Deal With Ryvu Therapeutics

by Zacks Equity Research

BioNTech (BNTX) signs a research collaboration agreement with Ryvu Therapeutics to develop small molecule programs targeting immune modulation in cancer and other diseases. Stock up.

Novavax (NVAX) COVID Jab Gets Expanded Label in WHO's EUL

by Zacks Equity Research

The WHO updates Emergency Use Listing (EUL) for Novavax's (NVAX) COVID-19 vaccine to include its use as a primary series in adolescents and for use as a booster dose in adults.

BioNTech SE Sponsored ADR (BNTX) Just Overtook the 20-Day Moving Average

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

Novavax (NVAX) Stock Nosedives 88% This Year: Here's Why

by Zacks Equity Research

Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.

Novavax (NVAX) Cancels COVID Jab Supply Deal With GAVI

by Zacks Equity Research

Novavax (NVAX) claims that GAVI's failure to procure its COVID vaccine doses is a reason to terminate the supply agreement. GAVI denies the company's claims and a legal battle is likely to follow.

Pfizer (PFE), BioNTech Provide New Data on BA.4/BA.5 Boosters

by Zacks Equity Research

Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccines show improved immune response against newer Omicron sublineages.

Moderna's (MRNA) Omicron BA.4/5 Booster Jab Study Meets Goal

by Zacks Equity Research

Moderna's (MRNA) Omicron-targeting bivalent COVID vaccines exhibit substantial antibody response compared with an original booster dose of Spikevax.

Sanofi (SNY), GSK Receive EU Approval for COVID-19 Vaccine

by Zacks Equity Research

Sanofi (SNY) and partner GSK's COVID-19 vaccine receives authorization in the European Union for use as a booster in adults aged 18 years and older.

Novavax (NVAX) Q3 Earnings Miss, Lowers '22 Sales Outlook

by Zacks Equity Research

Novavax (NVAX) reports mixed results in second-quarter 2022. Management lowers guidance for 2022.

BioNTech (BNTX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On BioNTech's (BNTX) third-quarter earnings call, investors will likely focus on the sales performance of its COVID-19 vaccine Comirnaty, developed in partnership with Pfizer.

Pfizer (PFE) Beats on Q3 Earnings, Ups COVID Jab Sales View

by Zacks Equity Research

Pfizer (PFE) beats estimates for Q3 earnings and sales. It ups its sales and earnings view despite a decline in COVID-19 vaccine sales in Q3. Stock up in pre-market trading

Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus is likely to be on sales numbers of Pfizer's (PFE) COVID-19 vaccine and COVID pill, Paxlovid.

Moderna (MRNA) Gets CHMP Nod for Omicron BA.4, BA.5 Booster Jab

by Zacks Equity Research

The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.4/5 subvariants, for use in adults and adolescents aged 12 years and older.

Novavax (NVAX) Receives FDA Nod for COVID-19 Booster Jab

by Zacks Equity Research

Novavax (NVAX) gets FDA authorization for using its COVID vaccine as a booster dose in adults after six months of completing the primary vaccine regimen.

Reata Pharmaceuticals, Inc. (RETA) Stock Jumps 20.6%: Will It Continue to Soar?

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Novavax (NVAX) Reports Positive Data on COVID/FLU Combo Jab Study

by Zacks Equity Research

Novavax (NVAX) reports positive data from its phase I/II study evaluating a combination of its COVID-19 and the seasonal influenza vaccine.

Pfizer (PFE) Posts Positive Data on Bivalent BA.4/5 COVID Jab

by Zacks Equity Research

Pfizer (PFE) and partner BioNTech's Omicron BA.4/BA.5-adapted bivalent COVID vaccine exhibits substantial antibody response above pre-booster levels in adults after seven days of dose administration.

The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna, Merck and GSK

by Zacks Equity Research

Pfizer, BioNTech, Moderna, Merck and GSK are included in this Analyst Blog.